Protection cardio-renale par les inhibiteurs des SGLT2 (gliflozines) : d'EMPA-REG OUTCOME a CANVAS.

[en] The cardiovascular (CV) and renal protection reported with empagliflozin in EMPA-REG OUTCOME is now confirmed with canagliflozin in CANVAS in patients with type 2 diabetes and high cardiovascular risk: similar and significant reductions in major CV events (-14 vs. -14%), in hospitalisations for heart failure (-35 vs. -33%) and in renal events (-39 vs. -40%). The greater reduction in CV mortality (-38 vs. - 13%) and all-cause mortality (-32 vs. -13%) in EMPA-REG OUTCOME than in CANVAS may be explained by the greater proportion of patients with CV disease (secondary prevention : 99 vs. 65%). In contrast to EMPA-REG OUTCOME, CANVAS did not show an increase in stroke (-10%, NS), but reported a higher rate of fractures and amputations with canagliflozin. Overall, these results support a class effect for the cardiorenal protection by inhibitors of sodium-glucose type 2 (SGLT2) cotransporters.

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège > Département des sciences cliniques > Département des sciences cliniques

Ernest, Philippe

Jandrain, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de diabétologie, nutrition, maladies métaboliques

Language :

French

Title :

Protection cardio-renale par les inhibiteurs des SGLT2 (gliflozines) : d'EMPA-REG OUTCOME a CANVAS.

Alternative titles :

[en] Cardiorenal protection with SGLT2 inhibitors (gliflozins) : from EMPA-REG OUTCOME to CANVAS

Publication date :

2017

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Volume :

Issue :

571

Pages :

1421-1426

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 08 October 2017

Statistics

Number of views

1086 (12 by ULiège)

Number of downloads

1086 (7 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Scheen AJ. SGLT2 inhibitors : Benefit/risk balance. Curr Diabetes Rep 2016;16:92.
Scheen AJ, Paquot N. Actualisation 2015 du traitement de lhyperglycémie dans le diabète de type 2. Rev Med Suisse 2015;11:1518-25.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-Transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33-59.
Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk : Proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015;12:90-100.
Ghosh RK, Bandyopadhyay D, Hajra A, et al. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors : A comprehensive review of clinical and preclinical studies. Int J Cardiol 2016;212:29-36.
Scheen AJ, Wallemacq C, Jandrain B, et al. Protection cardiovasculaire du patient diabétique de type 2 : dEMPA-REG OUTCOME à LEADER. Rev Med Suisse 2016;12:1370-5.
Scheen AJ. Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial : A critical analysis. Diabetes Metab 2016;42:71-6.
Sattar N, McLaren J, Kristensen SL, et al. SGLT2 inhibition and cardiovascular events : Why did EMPA-REG Outcomes surprise and what were the likely mechanisms ? Diabetologia 2016;59:1333-9.
Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes : Cardiovascular and kidney effects. Potential mechanisms and clinical applications. Circulation 2016;134:752-72.
Plosker GL. Canagliflozin : A review of its use in patients with type 2 diabetes mellitus. Drugs 2014;74:807-24.
Deeks ED, Scheen AJ. Canagliflozin : A review in type 2 diabetes. Drugs 2017; in press.
Plosker GL. Dapagliflozin : A review of its use in patients with type 2 diabetes. Drugs 2014;74:2191-209.
Scheen AJ. Historique des études cardiovasculaires : de lUGDP aux dernières études. Médecine des maladies Métaboliques 2017;11:2S15-2S26.
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; epub ahead of print.
Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPAREG OUTCOME). Cardiovasc Diabetol 2014;13:102.
Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk : Results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016;37:1526-34.
Zinman B, Inzucchi SE, Lachin JM, et al. Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk. Stroke 2017;48:1218-25.
Scheen AJ. SGLT2 inhibition : Efficacy and safety in type 2 diabetes treatment. Exp Opin Drug Safety 2015;14:1879-904.
Neal B, Perkovic V, Mahaffey KW, et al. Optimizing the analysis strategy for the CANVAS Program : A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 2017;19:926-35.
Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial. Am Heart J 2013;166:217-23 e11.
Neal B, Perkovic V, Matthews DR, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Diabetes Obes Metab 2017;19:387-93.
Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016;101:157-66.
McMurray J. EMPA-REG-The diuretic hypothesis . J Diabetes Complications 2016;30:3-4.
Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 2016;9:1860-70.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200.
Heerspink HJ, Desai M, Jardine M, et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2017;28:368-75.
Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL study. Circulation 2017; epub ahead of print.
Mudaliar S, Alloju SHenry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study ? A unifying hypothesis. Diabetes Care 2016;39:1115-22.
Scheen AJ. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes : Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Res Clin Pract 2016;121:204-14.
Scheen AJ, Delanaye P. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes : Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Metab 2017;43:99-109.
American Diabetes Association. Standards of medical care in diabetes-2017. Diabetes Care 2017;40:S1-S135.